Functionalized fluorine containing phthalocyanine molecules
Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.
1. A functionalized fluorine containing phthalocyanine represented by Formula (I):
wherein each R f is independently selected from the group consisting of —C(CF 3 ) 2 F and a fluorine atom (—F),
wherein at least one R f includes a fluorine atom,
wherein each R′ is a hydrogen atom,
wherein M is selected from the group consisting of Zn 2+ , Mg 2+ , low-spin Fe 2+ , Ru 2+ , Pt 2+ , Ti 4+ , Si 4+ , and two protons (H + ), and
wherein R includes at least one ligand selected from the group consisting of a peptide selected from SEQ ID NO: 17-41, and an oligonucleotide selected from SEQ ID NO: 1-16.
2. The functionalized fluorine containing phthalocyanine of claim 1 , wherein R includes at least one ligand that is an oligonucleotide selected from SEQ ID NO: 1-16, and further comprising:
a second oligonucleotide, wherein
the second oligonucleotide is complementary to the oligonucleotide selected from SEQ ID NO: 1-16.
3. A pharmaceutical composition including the functionalized fluorine containing phthalocyanine of claim 1 and a pharmaceutical acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein R includes at least one ligand that is an oligonucleotide selected from SEQ ID NO: 1-16, and wherein the fluorine containing phthalocyanine further comprises:
a second oligonucleotide, wherein
the second oligonucleotide is complementary to the oligonucleotide selected from SEQ ID NO: 1-16.
5. The functionalized fluorine containing phthalocyanine of claim 1 , wherein the at least one ligand is an oligonucleotide selected from SEQ ID NO: 1-16, and wherein R further comprises —(CH 2 ) 6 —.
6. The functionalized fluorine containing phthalocyanine of claim 5 , wherein the at least one ligand is an oligonucleotide of SEQ ID NO: 16, and wherein M is Zn 2+ .
7. The functionalized fluorine containing phthalocyanine of claim 1 , wherein the at least one ligand is an oligonucleotide of SEQ ID NO: 16, and wherein M is Zn 2+ .
8. The pharmaceutical composition of claim 7 , wherein the fluorine containing phthalocyanine further comprises:
a second oligonucleotide, wherein
the second oligonucleotide is complementary to the oligonucleotide selected from SEQ ID NO: 1-16.
9. A pharmaceutical composition including the functionalized fluorine containing phthalocyanine of claim 8 and a pharmaceutical acceptable carrier.